Robust association of the LPAlocus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment

Authors :: Donnelly, Louise A.
Zuydam, Natalie R. van
Zhou, Kaixin
Tavendale, Roger
Carr, Fiona
Zee, Anke H. Maitland-van der
Leusink, Maarten
de Boer, Anthonius
Doevendans, Pieter A.
Asselbergs, Folkert W.
Morris, Andrew D.
Pearson, Ewan R.
Klungel, Olaf H.
Doney, Alex S.F.
Palmer, Colin N.A.
Source :: Pharmacogenetics and Genomics; October 2013, Vol. 23 Issue: 10 p518-525, 8p
Publication Year :: 2013
Abstract: The LPAsingle-nucleotide polymorphism rs10455872 has been associated with low-density lipoprotein cholesterol (LDLc) lowering response to statins in several randomized control trials (RCTs) and is a known coronary artery disease (CAD) marker. However, it is unclear what residual risk of CAD this marker may have during statin treatment.

Full Text Access

Tools